MetaVia Inc. announces positive statistically significant results from the Phase 1b clinical trial of DA-1726, a novel treatment for obesity.
The trial demonstrated strong glycemic response, significant direct hepatic effects, and robust weight loss, with a favorable safety profile.
Patients experienced reductions in waist circumference, liver stiffness, and fasting glucose levels over the 8-week period.
Weight Loss
Patients achieved a 9.1% reduction in weight (21.2 lbs) by Day 54.
Waist Circumference
A significant 9.8 cm reduction in waist circumference was observed by Day 54.
Glucose Control
Patients showed a 12.3 mg/dL improvement in fasted glucose levels.
Liver Stiffness
Vibration-controlled transient elastography indicated a 23.7% reduction in liver stiffness.
Future Studies
Planned titration studies aim to further evaluate the efficacy and tolerability of DA-1726.
- The results highlight DA-1726's potential as a best-in-class treatment option for obesity and metabolic diseases.
- The findings suggest that DA-1726 offers a differentiated approach with significant weight loss and metabolic improvements.
- The observed reductions in waist circumference and liver stiffness indicate the drug's positive impact on visceral fat and hepatic health.
The Phase 1 clinical trial of DA-1726 by MetaVia Inc. has shown promising results in weight loss, glucose control, and hepatic effects, positioning the drug as a potential game-changer in the treatment of obesity.